• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Nasus Pharma Ltd.

    4/7/26 5:12:51 PM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NSRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Nasus Pharma Ltd

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)




    M7071P109

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    M7071P109


    1Names of Reporting Persons

    Funicular Funds, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    612,913.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    612,913.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    612,913.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The reporting person's beneficial ownership consists of 612,913 Ordinary Shares (the "Shares"). The foregoing calculation is based upon 11,710,808 Shares outstanding as reported by the Issuer in Post-Effective Amendment No. 1 to Form F-1 with the Securities and Exchange Commission on March 27, 2026.


    SCHEDULE 13G

    CUSIP Number(s):
    M7071P109


    1Names of Reporting Persons

    Cable Car Capital, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    612,913.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    612,913.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    612,913.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    PN, IA

    Comment for Type of Reporting Person:  The reporting person's beneficial ownership consists of 612,913 Shares. The foregoing calculation is based upon 11,710,808 Shares outstanding as reported by the Issuer in Post-Effective Amendment No. 1 to Form F-1 with the Securities and Exchange Commission on March 27, 2026. Cable Car Capital, LP, as the General Partner of Funicular Funds, LP, and Jacob Ma-Weaver, as the Managing Member of Cable Car Capital, LP, may each be deemed the beneficial owner of the Shares held by Funicular Funds, LP.


    SCHEDULE 13G

    CUSIP Number(s):
    M7071P109


    1Names of Reporting Persons

    Ma-Weaver Jacob
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    612,913.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    612,913.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    612,913.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  The reporting person's beneficial ownership consists of 612,913 Shares. The foregoing calculation is based upon 11,710,808 Shares outstanding as reported by the Issuer on Post-Effective Amendment No. 1 to Form F-1 with the Securities and Exchange Commission on March 27, 2026. Cable Car Capital, LP, as the General Partner of Funicular Funds, LP, and Jacob Ma-Weaver, as the Managing Member of Cable Car Capital, LP, may each be deemed the beneficial owner of the Shares held by Funicular Funds, LP.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Nasus Pharma Ltd
    (b)Address of issuer's principal executive offices:

    29 HARAKEVET ST, TEL AVIV - YAFO, ISRAEL, 6618003.
    Item 2. 
    (a)Name of person filing:

    Funicular Funds, LP Cable Car Capital, LP Jacob Ma-Weaver
    (b)Address or principal business office or, if none, residence:

    601 California Street, Suite 1151, San Francisco, CA 94108
    (c)Citizenship:

    Funicular Funds, LP - Delaware Cable Car Capital, LP - Delaware Jacob Ma-Weaver - United States
    (d)Title of class of securities:

    Ordinary Shares
    (e)CUSIP Number(s):

    M7071P109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Funicular Funds, LP - 612,913 Cable Car Capital, LP - 612,913 Jacob Ma-Weaver - 612,913
    (b)Percent of class:

    Funicular Funds, LP - 5.2% Cable Car Capital, LP - 5.2% Jacob Ma-Weaver - 5.2%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Funicular Funds, LP - 612,913 Cable Car Capital, LP - 612,913 Jacob Ma-Weaver - 612,913

     (ii) Shared power to vote or to direct the vote:

    Funicular Funds, LP - 0 Cable Car Capital, LP - 0 Jacob Ma-Weaver - 0

     (iii) Sole power to dispose or to direct the disposition of:

    Funicular Funds, LP - 612,913 Cable Car Capital, LP - 612,913 Jacob Ma-Weaver - 612,913

     (iv) Shared power to dispose or to direct the disposition of:

    Funicular Funds, LP - 0 Cable Car Capital, LP - 0 Jacob Ma-Weaver - 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Funicular Funds, LP
     
    Signature:Jacob Ma-Weaver
    Name/Title:Managing Member of the General Partner
    Date:04/07/2026
     
    Cable Car Capital, LP
     
    Signature:Jacob Ma-Weaver
    Name/Title:Managing Member
    Date:04/07/2026
     
    Ma-Weaver Jacob
     
    Signature:Jacob Ma-Weaver
    Name/Title:Jacob Ma-Weaver
    Date:04/07/2026
    Exhibit Information

    Exhibit A

    Get the next $NSRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NSRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NSRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

    Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4 2026 Company advancing pipeline assets NS003 (Ondansetron for chemotherapy-induced nausea and vomiting) and NS004 (metabolic) toward first-in-human studies expected to start in the second half of 2026, significantly expanding the Company's intranasal product portfolio into additional high value therapeutic areas Company well funded through planned NS002 pivotal study and potential NDA submission TEL AVIV, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSR

    3/25/26 9:00:00 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript

    In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis. The study demonstrated a statistically significant and clinically meaningful advantage over EpiPen in time to therapeutic threshold (T100), with NS002 reaching effective epinephrine levels in a median of 1.69 minutes compared to 3.42 minutes for EpiPen. At 2.5 minutes, 67.4% of participants receiving NS002 had already reached therapeutic levels versus 27.1% with EpiPen, with the advantage persisting through the 5-minute mark. Across the critical early treatment wind

    3/19/26 10:05:58 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

    NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth quarter of 2026 Conference call and webcast scheduled for 8:00 a.m. EDT today TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"),

    3/16/26 7:30:00 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NSRX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Nasus Pharma Ltd.

    SCHEDULE 13G - Nasus Pharma Ltd (0002029039) (Subject)

    4/7/26 5:12:51 PM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Nasus Pharma Ltd.

    EFFECT - Nasus Pharma Ltd (0002029039) (Filer)

    4/1/26 12:15:28 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS AM filed by Nasus Pharma Ltd.

    POS AM - Nasus Pharma Ltd (0002029039) (Filer)

    3/27/26 5:24:12 PM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NSRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Teleman Dan Benjamin

    4 - Nasus Pharma Ltd (0002029039) (Issuer)

    4/22/26 9:44:10 PM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Teleman Dan Benjamin

    4 - Nasus Pharma Ltd (0002029039) (Issuer)

    4/1/26 7:31:31 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Rubin Eyal

    3 - Nasus Pharma Ltd (0002029039) (Issuer)

    3/27/26 9:37:27 PM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NSRX
    Leadership Updates

    Live Leadership Updates

    View All

    Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

    TEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer. Mr. Rubin brings more than two decades of financial leadership experience in global biotechnology and pharmaceutical industries to Nasus Pharma's executive leadership team. Mr. Rubin will lead and oversee Nasus Pharma's financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as

    11/20/25 8:15:00 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NSRX
    Financials

    Live finance-specific insights

    View All

    BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript

    In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis. The study demonstrated a statistically significant and clinically meaningful advantage over EpiPen in time to therapeutic threshold (T100), with NS002 reaching effective epinephrine levels in a median of 1.69 minutes compared to 3.42 minutes for EpiPen. At 2.5 minutes, 67.4% of participants receiving NS002 had already reached therapeutic levels versus 27.1% with EpiPen, with the advantage persisting through the 5-minute mark. Across the critical early treatment wind

    3/19/26 10:05:58 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

    NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth quarter of 2026 Conference call and webcast scheduled for 8:00 a.m. EDT today TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"),

    3/16/26 7:30:00 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

    TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of the Company's management will host a conference call and webcast on Monday, March 16, 2026, at 8:00 a.m. ET to present and discuss the topline analysis from the Phase 2 repeated dose clinical study of NS002, the Company's intranasal powder epinephrine product candidate. A question-and-answer session will follow the data presentation. Conference call & webcast info: Monday, March 16, 2026, at 08:00 a.m. ETIndividuals may register for the webcast at

    3/9/26 8:30:00 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care